D. B. Smith, J. Bukh, and C. Kuiken, Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource Hepatology, vol.59, pp.318-327, 2014.

S. M. Borgia, C. Hedskog, and B. Parhy, Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. The Journal of Infectious Diseases, 2018.

V. D. Thong, Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication, World Journal of Gastroenterology, vol.20, issue.11, p.2927, 2014.

C. Li, E. Barnes, and P. N. Newton, An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes, Virology, vol.476, pp.355-363, 2015.

W. Seto, C. Lai, and J. Fung, Natural history of chronic hepatitis C: genotype 1 versus genotype 6, Journal of Hepatology, vol.53, issue.3, pp.444-448, 2010.

M. Lee, T. I. Hsiao, and S. R. Subramaniam, HCV genotype 6 increased the risk for hepatocellular carcinoma among Asian patients with liver cirrhosis, The American Journal of Gastroenterology, vol.112, issue.7, pp.1111-1119, 2017.

, EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J Hepatol, vol.60, issue.2, 2014.

G. Cheng, Y. Tian, and B. Doehle, In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5a inhibitor ledipasvir, Antimicrobial Agents and Chemotherapy, vol.60, issue.3, pp.1847-1853, 2016.

L. V. Pham, S. Ramirez, and J. M. Gottwein, HCV genotype 6a escape from and resistance to velpatasvir, pibrentasvir, and sofosbuvir in robust infectious cell culture models, Gastroenterology, vol.154, issue.8, pp.2194-2208, 2018.

F. Mcphee, J. Ueland, V. Vellucci, S. Bowden, W. Sievert et al., Impact of preexisting hepatitis c virus genotype 6 NS3, NS5A, and NS5B polymorphisms on the in vitro potency of direct-acting antiviral agents, Antimicrob Agents Chemother, vol.63, issue.4, 2019.

G. Schnell, P. Krishnan, and R. Tripathi, Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir, PLoS ONE, vol.13, issue.10, p.205186, 2018.

M. C. Sorbo, V. Cento, D. Maio, and V. C. , Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update, Drug Resistance Updates, vol.37, pp.17-39, 2018.

E. Andre-garnier, B. Besse, and A. Rodallec, An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains. Jhaveri R, ed. PLOS ONE, vol.12, p.179562, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02155275

S. Kumar, G. Stecher, and K. Tamura, MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets, Molecular Biology and Evolution, vol.33, issue.7, pp.1870-1874, 2016.

P. Bruggmann, T. Berg, and A. Øvrehus, Historical epidemiology of hepatitis C virus (HCV) in selected countries, J Viral Hepat, vol.21, pp.5-33, 2014.

R. Yang, X. Cong, S. Du, R. Fei, H. Rao et al., Performance comparison of the Versant HCV genotype 2.0 assay (LiPA) and the Abbott Realtime HCV genotype II assay for detecting hepatitis C virus genotype 6, J Clin Microbiol, vol.52, issue.10, pp.3685-3692, 2014.

S. Larrat, J. Poveda, and C. Coudret, Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0, J Clin Microbiol, vol.51, issue.9, pp.2815-2821, 2013.

B. Némoz, L. Roger, V. Leroy, J. Poveda, P. Morand et al., Evaluation of the cobas® GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures, PLOS ONE, vol.13, issue.3, p.194396, 2018.

N. Chueca, I. Rivadulla, and R. Lovatti, Using NS5B sequencing for hepatitis C virus genotyping reveals discordances with commercial platforms, PLoS ONE, vol.11, issue.4, p.153754, 2016.

M. Ye, X. Chen, Y. Wang, L. Duo, C. Zhang et al., Identification of a new HCV subtype 6xg among injection drug users in Kachin, Myanmar. Frontiers in Microbiology, vol.10, 2019.

S. D. Boyd, P. Harrington, and T. E. Komatsu, HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens, J Viral Hepat, vol.25, issue.8, pp.969-975, 2018.

C. Hezode, N. Reau, and E. S. Svarovskaia, Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies, J Hepatol, vol.68, issue.5, pp.895-903, 2018.

L. V. Pham, S. B. Jensen, and U. Fahnøe, HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape, J Hepatol, vol.70, issue.3, pp.388-397, 2019.

S. B. Jensen, S. Serre, and D. G. Humes, Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance, Antimicrobial Agents and Chemotherapy, vol.59, issue.12, pp.7426-7436, 2015.

J. George, E. Burnevich, and I. Sheen, Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection, Hepatol Commun, vol.2, issue.5, pp.595-606, 2018.

C. Wang, L. Jia, O. Boyle, and D. R. , Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity, Antimicrobial Agents and Chemotherapy, vol.58, issue.9, pp.5155-5163, 2014.

T. I. Ng, P. Krishnan, and T. Pilot-matias, In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5a inhibitor pibrentasvir, Antimicrobial Agents and Chemotherapy, vol.61, issue.5, pp.2558-2574, 2017.

G. Cheng, M. Yu, and B. Peng, GS-5816, a second generation HCV NS5a inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier, Journal of Hepatology, vol.58, issue.13, pp.61192-61199, 2013.

S. Xu, B. Doehle, and S. Rajyaguru, In vitro selection of resistance to sofosbuvir in HCV replicons of genotype 1 to 6, Antiviral Therapy, vol.22, issue.7, pp.587-597, 2017.

Z. Li, Y. Liu, and Y. Zhang, Naturally occurring resistance-associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 6a-infected patients, BioMed Research International, vol.2017, pp.1-8, 2017.

E. J. Gane, R. H. Hyland, and D. An, Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection, Gastroenterology, vol.149, issue.6, pp.1454-1461, 2015.